Evidence map›Paper›PMID 37861336›Full record

ArticleJournal of virology2023

Blocking of doublecortin-like kinase 1-regulated SARS-CoV-2 replication cycle restores cell signaling network.

Ram Babu Undi, Nagib Ahsan, Jason L Larabee, Nicole Darlene-Reuter, James Papin, Samrita Dogra, Bethany N Hannafon, Michael S Bronze, Courtney W Houchen, Mark M Huycke and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ram Babu UndiDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.
Nagib AhsanDepartment of Chemistry and Biochemistry, University of Oklahoma , Norman, Oklahoma, USA.
Jason L LarabeeDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.
Nicole Darlene-ReuterDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.
James PapinDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.ORCID 0000-0001-9894-8243
Samrita DograPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.
Bethany N HannafonPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.
Michael S BronzeDigestive Diseases and Nutrition, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.
Courtney W HouchenPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.
Mark M HuyckeDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.
Naushad AliPeggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, USA.ORCID 0000-0002-0058-7396
University of Oklahoma Health Sciences Center · USUniversity of Oklahoma · US

Funding

Proteomics CoreP20GM103447 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI David W Dyer · 2012 to 2026
$60.2M
Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
Microbiome-triggered reprogramming and mutation of colon epithelial cells leading to tumor stem-like cellsR01CA230641 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HUYCKE, MARK M · 2019 to 2023
$2.3M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA230641NIGMS NIH HHS P20 GM103447NIGMS NIH HHS P20 GM103639
6 · The paper itself

Abstract

importanceSevere COVID-19 and post-acute sequelae often afflict patients with underlying co-morbidities. There is a pressing need for highly effective treatment, particularly in light of the emergence of SARS-CoV-2 variants. In a previous study, we demonstrated that DCLK1, a protein associated with cancer stem cells, is highly expressed in the lungs of COVID-19 patients and enhances viral production and hyperinflammatory responses. In this study, we report the pivotal role of DCLK1-regulated mechanisms in driving SARS-CoV-2 replication-transcription processes and pathogenic signaling. Notably, pharmacological inhibition of DCLK1 kinase during SARS-CoV-2 effectively impedes these processes and counteracts virus-induced alternations in global cell signaling. These findings hold significant potential for immediate application in treating COVID-19.

Indexed as

COVID-19COVID-19 Drug TreatmentDoublecortin-Like KinasesHumansProtein Serine-Threonine KinasesSARS-CoV-2Signal TransductionVirus ReplicationDCLK1 protein, humanDoublecortin-Like KinasesProtein Serine-Threonine Kinasescell signalingCOVID-19DCLK1DCLK1-IN-1host-virus interactioninteractomepathologyreplication-transcriptionSARS-CoV-2

Identifiers

PMID37861336
PMCPMC10688311
OpenAlexW4387799014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.